Palvella Therapeutics (PVLA) – Investment Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Palvella Therapeutics (NASDAQ: PVLA) recently:

• 12/29/2025 – Palvella Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Palvella Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/16/2025 – Palvella Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/16/2025 – Palvella Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $148.00 to $204.00. They now have a “buy” rating on the stock.
• 12/16/2025 – Palvella Therapeutics had its “strong-buy” rating reaffirmed by analysts at Raymond James Financial, Inc.. They now have a $193.00 price target on the stock.
• 12/16/2025 – Palvella Therapeutics had its price target raised by analysts at TD Cowen from $97.00 to $133.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Palvella Therapeutics had its price target raised by analysts at Chardan Capital from $110.00 to $174.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Palvella Therapeutics had its price target raised by analysts at BTIG Research from $167.00 to $192.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Palvella Therapeutics had its price target raised by analysts at Truist Financial Corporation from $105.00 to $190.00. They now have a “buy” rating on the stock.
• 12/15/2025 – Palvella Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Palvella Therapeutics had its “buy” rating reaffirmed by analysts at UBS Group AG. They now have a $143.00 price target on the stock.
• 12/15/2025 – Palvella Therapeutics was given a new $200.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
• 12/15/2025 – Palvella Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc.. They now have a $200.00 price target on the stock.
• 12/11/2025 – Palvella Therapeutics had its price target raised by analysts at HC Wainwright to $190.00. They now have a “buy” rating on the stock.
• 12/8/2025 – Palvella Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 12/5/2025 – Palvella Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $167.00 price target on the stock.
• 12/5/2025 – Palvella Therapeutics is now covered by analysts at BTIG Research. They set a “buy” rating and a $167.00 price target on the stock.
• 12/4/2025 – Palvella Therapeutics is now covered by analysts at Craig Hallum. They set a “buy” rating and a $175.00 price target on the stock.
• 12/4/2025 – Palvella Therapeutics is now covered by analysts at Craig Hallum. They set a “buy” rating and a $175.00 price target on the stock.
• 12/1/2025 – Palvella Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Palvella Therapeutics had its “sell (d)” rating reaffirmed by analysts at Weiss Ratings.
• 11/24/2025 – Palvella Therapeutics had its price target raised by analysts at Stifel Nicolaus from $87.00 to $145.00. They now have a “buy” rating on the stock.
• 11/19/2025 – Palvella Therapeutics was upgraded by analysts at Raymond James Financial, Inc. from an “outperform” rating to a “strong-buy” rating. They now have a $143.00 price target on the stock, up previously from $92.00.
• 11/13/2025 – Palvella Therapeutics had its price target raised by analysts at Canaccord Genuity Group Inc. from $90.00 to $148.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Palvella Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $110.00 price target on the stock.
• 11/11/2025 – Palvella Therapeutics had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
• 11/10/2025 – Palvella Therapeutics had its price target raised by analysts at Truist Financial Corporation from $80.00 to $105.00. They now have a “buy” rating on the stock.
• 11/7/2025 – Palvella Therapeutics had its price target raised by analysts at Chardan Capital from $73.00 to $110.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Palvella Therapeutics had its price target raised by analysts at TD Cowen from $65.00 to $97.00. They now have a “buy” rating on the stock.
• 11/6/2025 – Palvella Therapeutics had its price target raised by analysts at Cantor Fitzgerald from $120.00 to $200.00. They now have an “overweight” rating on the stock.
• 11/6/2025 – Palvella Therapeutics had its price target raised by analysts at HC Wainwright from $95.00 to $190.00. They now have a “buy” rating on the stock.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total transaction of $415,013.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.50% of the company’s stock.

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.